Document Detail

Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
MedLine Citation:
PMID:  6604099     Owner:  NLM     Status:  MEDLINE    
Other investigators have reported activation of the alternative complement (C) pathway in homologous and heterologous serum by a variety of human lymphoblastoid B cell lines. Their ability to activate the C was associated with Epstein Barr virus transformation of the cells. We report that some human lymphoblastoid T cell lines, lacking EBV-DNA in their genome, do activate the human alternative C pathway with no participation of immunoglobulin or specific antibodies. Nevertheless, activation measured by C3 deposition on the cell surface was weaker than with the B cell lines so far studied; in relation to the RAJl cells, C3 deposition on JURKAT, MOLT 4, HSB2, and 1301 was, respectively, 68, 38, 28, and 19%. Furthermore, C3 deposition on JURKAT T cell line requires D, whereas RAJl cells provide a proteolytic activity able to mimic D, and which, unlike D, can be controlled by serum protease inhibitors. Although the ability to activate the AP seems to be a largely shared property of the human lymphoblastoid B and T cell lines, the situation was strikingly different with normal and mitogen-stimulated lymphocytes or with acute leukemic cells, which led to a negligible AP-dependent C3 deposition compared with the level observed with the lymphoblastoid cell lines. Membrane sialic acid content was determined for every cell tested and revealed no relationship with their ability to activate the AP. The two EBV+ B cell lines tested led to a comparable AP activation regardless of the presence of the C3b receptor.
F Praz; P Lesavre
Related Documents :
21132369 - Nucleus pulposus cell response to confined and unconfined compression implicates mechan...
12082029 - Single copy heterozygote integration of hpv 33 in chromosomal band 5p14 is found in an ...
8167899 - Comparison of oligosaccharide processing among various insect cell lines expressing a s...
19287999 - More than 45% of a549 and h446 cells are cancer initiating cells: evidence from cloning...
2066379 - Applications of immortalized cells in basic and clinical neurology.
10030849 - Respiratory carcinoma cell lines. muc genes and glycoconjugates.
12194309 - Development of the large scale digital cell analysis system.
2702679 - Retention of immunogenicity after x-irradiation of mouse colon tumor cells expressing t...
11703379 - Regulation of rheumatoid synoviocyte proliferation by endogenous p53 induction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of immunology (Baltimore, Md. : 1950)     Volume:  131     ISSN:  0022-1767     ISO Abbreviation:  J. Immunol.     Publication Date:  1983 Sep 
Date Detail:
Created Date:  1983-10-08     Completed Date:  1983-10-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985117R     Medline TA:  J Immunol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1396-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
B-Lymphocytes / immunology*
Cell Line
Complement Activation*
Complement C3 / metabolism
Complement Pathway, Alternative*
Leukemia, Lymphoid / immunology
Lymphocyte Activation*
Mitogens / pharmacology
Sialic Acids / analysis
T-Lymphocytes / immunology*
Reg. No./Substance:
0/Complement C3; 0/Mitogens; 0/Sialic Acids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The presence of NK alloantigens on cloned cytotoxic T lymphocytes.
Next Document:  Inhibition of mitogen-induced lymphocyte proliferation by ouabain: interference with interleukin 2 p...